Formulation and optimization of oxaliplatin immuno-nanoparticles using Box–Behnken design and cytotoxicity assessment for synergistic and receptor-mediated targeting in the treatment of colorectal cancer

References

• Anari E, Akbarzadeh A, Zarghami N. 2015. Chrysin-loaded PLGA-PEG nanoparticles designed for enhanced effect on the breast cancer cell line. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi:10.3109/21691401.2015.1029633.
   PubMed Web of Science ®Google Scholar
• Cavalli R, Morela S, Gasco MR, Chetonib AP, Saettoneb MF. 1995. Preparation and evaluation in vitro of colloidal lipospheres containing pilocarpine as ion pair. Int J Pharm. 117:243–246.
   Web of Science ®Google Scholar
• Ciftci K, Groves MJ. 1996. Delivery of antitumor compounds to the rat colon: in vitro and in vivo evaluation. Int J Pharm. 145:157–164.
   Web of Science ®Google Scholar
• Cirstoiu-Hapca A., Buchegger F, Lange N, Bossy L, Gurny R, Delie F. 2010. Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release. 144:324–331.
   PubMed Web of Science ®Google Scholar
• Colotta F. 2008. Anticancer drug discovery and development. In: Colotta F and Mantovani A, Eds. Targeted Therapies in Cancer, Springer, pp. 19–42.
   Google Scholar
• Domb AJ. 1996. Lipospheres for controlled delivery of substances. Drugs Pharm Sci. 73:377–410.
   Google Scholar
• Feng SS. 2011. Chemotherapeutic engineering: concept, feasibility, safety and prospect – a tribute to Shu Chien’s 80th birthday. Cel Mol Bioeng. 4:708–716.
   Web of Science ®Google Scholar
• Feng SS, Chien S. 2003. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci. 58:4087–4114.
   Google Scholar
• Feng SS, Zhao L, Zhang Z, Bhakta G, Win KY, Dong Y, Chien S. 2007. Chemotherapeutic engineering: vitamin E TPGS-emulsified nanoparticles of biodegradable polymers realized sustainable paclitaxel chemotherapy for 168h in vivo. Chem Eng Sci. 62:6641–6648.
   Google Scholar
• Hermanson GT. 2013. Bioconjugate Techniques. San Diego (CA): Academic Press.
   Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA. 95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Holoch PA, Griffith TS. 2009. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur J Pharmacol. 625:63–72.
   PubMed Web of Science ®Google Scholar
• Ishida O, Maruyama K, Sasaki K, Iwatsuru M. 1999. Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. Int J Pharm. 190:49–56.
   PubMed Web of Science ®Google Scholar
• Jain A, Gupta Y, Jain SK. 2007. Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci. 10:86–128.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK, Ganesh N, Barve J, Beg AM. 2010. Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine. 6:179–190.
   PubMed Web of Science ®Google Scholar
• Jain K, Sood S, Gowthamarajan K. 2014. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv. 22:940–954.
   PubMed Web of Science ®Google Scholar
• Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. 2009. Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov. 8:111–128.
   PubMed Web of Science ®Google Scholar
• Kurd K, Khandagi AA, Davaran S, Akbarzadeh A. 2015. Cisplatin release from dual-responsive magnetic nanocomposites. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi:10.3109/21691401.2015.1008513.
   PubMed Web of Science ®Google Scholar
• Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. 2007. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 120:18–26.
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y, Satyanarayana S. 2001. Colon-specific drug delivery systems. In: Jain NK, Ed. Advances in Controlled and Novel Drug Delivery. New Delhi, India: CBS Publishers and Distributors, pp. 89–119.
   Google Scholar
• LeBlanc H, Ashkenazi A. 2003. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. 10:66–75.
   PubMed Web of Science ®Google Scholar
• Lehár J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. 2009. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 27:659–666.
   PubMed Web of Science ®Google Scholar
• Maleki Dizaj S, Lotfipour F, Barzegar-Jalali M, Zarrintan MH, Adibkia K. 2015. Application of Box–Behnken design to prepare gentaicin-loaded calcium carbonate nanoparticles. Artif Cells Nanomed Biotechnol. [Epub ahead of print]. doi:10.3109/21691401.2015.1042108.
   PubMed Web of Science ®Google Scholar
• Maya S, Kumar LG, Sarmento B, Sanoj Rejinold N, Menon D, Nair SV, Jayakumar R. 2013. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr Polym. 93:661–669.
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Lengauer C, Nowak MA. 2005. Dynamics of colorectal cancer. Semin Cancer Biol. 15:484–93.
   PubMed Web of Science ®Google Scholar
• Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG. 2011. Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 29:1916–1923.
   PubMed Web of Science ®Google Scholar
• Mohideen B, Ezhilmuthu RP, Dhanalekshmi UM, Neelakanta Reddy P. 2013. Formulation and in-vitro characterization of gliclazide loaded polymeric nanoparticles. Int J Biol Pharm Res. 4:533–540.
   Google Scholar
• Muller RH, Mäder K, Gohla S. 2000. Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art. Eur J Pharm Biopharm. 50:161–177.
   PubMed Web of Science ®Google Scholar
• Prabaharan M, Reis RL, Mano JF. 2007. Carboxymethyl chitosan-graft-phosphatidylethanolamine: amphiphilic matrices for controlled drug delivery. React Funct Polym. 67:43–52.
   Web of Science ®Google Scholar
• Sheikh MS, Huang Y. 2004. Death receptors as targets of cancer therapeutics. Curr Cancer Drug Targets. 4:97–104.
   PubMed Web of Science ®Google Scholar
• Siekmann B, Westesen K. 1992. Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett. 1:123–126.
   Google Scholar
• Sood S, Jain K, Gowthamarajan K. 2014. Optimization of curcumin nanoemulsion for intranasal delivery using design of experiment and its toxicity assessment. Colloids Surf B Biointerfaces. 113:330–337.
   PubMed Web of Science ®Google Scholar
• Steinhauser I, Spänkuch B, Strebhardt K, Langer K. 2006. Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials. 27:4975–4983.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Subr V. 2004. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Deliv Rev. 56:1023–1050.
   PubMed Web of Science ®Google Scholar
• Vivek R, Thangam R, NipunBabu V, Rejeeth C, Sivasubramanian S, Gunasekaran P, Muthuchelian K, Kannan S. 2014. Multifunctional HER2-antibody conjugated polymeric nanocarrier-based drug delivery system for multi-drug-resistant breast cancer therapy. ACS Appl Mater Interfaces. 6:6469–6480.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 5:157–163.
   PubMed Web of Science ®Google Scholar
• Woodcock J, Griffin JP, Behrman RE. 2011. Development of novel combination therapies. N Engl J Med. 364:985–987.
   PubMed Web of Science ®Google Scholar